Mirum Pharmaceuticals (NasdaqGM:MIRM) - Share price, News & Analysis

MIRM fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	5/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

MIRM Stock Overview

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases.

Rewards

Trading at 89.8% below our estimate of its fair value

Earnings are forecast to grow 79.73% per year

Risk Analysis

Has less than 1 year of cash runway

Shareholders have been diluted in the past year

Mirum Pharmaceuticals Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Mirum Pharmaceuticals
Historical stock prices
Current Share Price	US$25.26
52 Week High	US$28.65
52 Week Low	US$12.82
Beta	1.23
1 Month Change	-1.60%
3 Month Change	5.56%
1 Year Change	59.47%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	91.22%

Shareholder Returns

	MIRM	US Biotechs	US Market
7D	5.2%	-3.2%	-4.0%
1Y	59.5%	-22.1%	-13.2%

Return vs Industry: MIRM exceeded the US Biotechs industry which returned -21.4% over the past year.

Return vs Market: MIRM exceeded the US Market which returned -12.3% over the past year.

Price Volatility

Is MIRM's price volatile compared to industry and market?
MIRM volatility
MIRM Average Weekly Movement	9.4%
Biotechs Industry Average Movement	12.4%
Market Average Movement	7.8%
10% most volatile stocks in US Market	16.8%
10% least volatile stocks in US Market	2.9%

Stable Share Price: MIRM is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: MIRM's weekly volatility (9%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2018	144	Chris Peetz	https://www.mirumpharma.com

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company’s lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis.

Mirum Pharmaceuticals Fundamentals Summary

How do Mirum Pharmaceuticals's earnings and revenue compare to its market cap?
MIRM fundamental statistics
Market Cap	US$801.91m
Earnings (TTM)	-US$70.06m
Revenue (TTM)	US$32.03m

25.0x

P/S Ratio

-11.4x

P/E Ratio

Is MIRM overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
MIRM income statement (TTM)
Revenue	US$32.03m
Cost of Revenue	US$4.33m
Gross Profit	US$27.70m
Other Expenses	US$97.77m
Earnings	-US$70.06m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	-2.21
Gross Margin	86.49%
Net Profit Margin	-218.74%
Debt/Equity Ratio	0%

How did MIRM perform over the long term?

See historical performance and comparison

Valuation

Is Mirum Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

>50%

Undervalued compared to fair value

Share Price vs. Fair Value

Below Fair Value: MIRM ($25.26) is trading below our estimate of fair value ($247.42)

Significantly Below Fair Value: MIRM is trading below fair value by more than 20%.

Price To Earnings Ratio

PE vs Industry: MIRM is unprofitable, so we can't compare its Price-To-Earnings Ratio to the US Biotechs industry average.

PE vs Market: MIRM is unprofitable, so we can't compare its Price-To-Earnings Ratio to the US market.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MIRM's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: MIRM is overvalued based on its Price-To-Book Ratio (7.4x) compared to the US Biotechs industry average (1.5x).

Future Growth

How is Mirum Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

Future Growth Score

5/6

Future Growth Score 5/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

79.7%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: MIRM is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).

Earnings vs Market: MIRM is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: MIRM's is expected to become profitable in the next 3 years.

Revenue vs Market: MIRM's revenue (48.6% per year) is forecast to grow faster than the US market (7.8% per year).

High Growth Revenue: MIRM's revenue (48.6% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: MIRM is forecast to be unprofitable in 3 years.

Past Performance

How has Mirum Pharmaceuticals performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

-31.9%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: MIRM is currently unprofitable.

Growing Profit Margin: MIRM is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: MIRM is unprofitable, and losses have increased over the past 5 years at a rate of 31.9% per year.

Accelerating Growth: Unable to compare MIRM's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MIRM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).

Return on Equity

High ROE: MIRM has a negative Return on Equity (-64.32%), as it is currently unprofitable.

Financial Health

How is Mirum Pharmaceuticals's financial position?

Financial Health Score

4/6

Financial Health Score 4/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: MIRM's short term assets ($155.3M) exceed its short term liabilities ($34.6M).

Long Term Liabilities: MIRM's short term assets ($155.3M) exceed its long term liabilities ($134.7M).

Debt to Equity History and Analysis

Debt Level: MIRM is debt free.

Reducing Debt: MIRM has not had any debt for past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MIRM has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if MIRM has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.

Dividend

What is Mirum Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate MIRM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MIRM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MIRM's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MIRM's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as MIRM has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.6yrs

Average management tenure

CEO

Chris Peetz (42 yo)

3.42yrs

Tenure

US$4,130,831

Compensation

Mr. Christopher Peetz, also known as Chris, serves as Entrepreneur-in-Residence at Frazier Management, L.L.C since May 30, 2017. He joined Frazier on May 30, 2017. He is on the Frazier Life Sciences team (...

CEO Compensation Analysis

Compensation vs Market: Chris's total compensation ($USD4.13M) is about average for companies of similar size in the US market ($USD3.85M).

Compensation vs Earnings: Chris's compensation has increased whilst the company is unprofitable.

Leadership Team

Experienced Management: MIRM's management team is considered experienced (2.6 years average tenure).

Board Members

Experienced Board: MIRM's board of directors are considered experienced (3 years average tenure).

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5%.

Data	Last Updated (UTC time)
Company Analysis	2022/05/24 00:00
End of Day Share Price	2022/05/24 00:00
Earnings	2022/03/31
Annual Earnings	2021/12/31